The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients.
With a €2 billion euro budget, IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, IMI aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D). IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally and establish Europe as the most attractive place for pharmaceutical R&D.
IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training. Projects are selected through open Calls for proposals.
The research consortia participating in IMI projects consist of:
- large biopharmaceutical companies that are members of EFPIA,
- and a variety of other partners, such as:
- small- and medium-sized enterprises,
- patients' organisations,
- universities and other research organisations,
- regulatory agencies,
- any other industrial partners.
IMI is a Joint Undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The European Commission's Seventh Framework Programme contributes €1 billion to the IMI research programme. That amount will be matched by mainly in kind contributions (consisting mostly of research activities) worth at least another €1 billion euro from member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).